OMGA vs. MOLN, KPTI, SCLX, LIFE, BCAB, VIGL, SGMO, BLUE, DBVT, and CRDL
Should you be buying Omega Therapeutics stock or one of its competitors? The main competitors of Omega Therapeutics include Molecular Partners (MOLN), Karyopharm Therapeutics (KPTI), Scilex (SCLX), aTyr Pharma (LIFE), BioAtla (BCAB), Vigil Neuroscience (VIGL), Sangamo Therapeutics (SGMO), bluebird bio (BLUE), DBV Technologies (DBVT), and Cardiol Therapeutics (CRDL). These companies are all part of the "medical" sector.
Molecular Partners (NASDAQ:MOLN) and Omega Therapeutics (NASDAQ:OMGA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.
Molecular Partners has higher revenue and earnings than Omega Therapeutics. Molecular Partners is trading at a lower price-to-earnings ratio than Omega Therapeutics, indicating that it is currently the more affordable of the two stocks.
Molecular Partners presently has a consensus target price of $4.50, suggesting a potential upside of 25.70%. Omega Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 336.68%. Given Molecular Partners' stronger consensus rating and higher possible upside, analysts clearly believe Omega Therapeutics is more favorable than Molecular Partners.
In the previous week, Omega Therapeutics had 7 more articles in the media than Molecular Partners. MarketBeat recorded 9 mentions for Omega Therapeutics and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.73 beat Omega Therapeutics' score of 0.30 indicating that Omega Therapeutics is being referred to more favorably in the news media.
Molecular Partners has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Omega Therapeutics has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500.
Omega Therapeutics received 12 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 71.88% of users gave Omega Therapeutics an outperform vote while only 44.00% of users gave Molecular Partners an outperform vote.
26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 97.5% of Omega Therapeutics shares are held by institutional investors. 5.9% of Molecular Partners shares are held by insiders. Comparatively, 57.0% of Omega Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Molecular Partners has a net margin of -885.11% compared to Molecular Partners' net margin of -1,868.35%. Omega Therapeutics' return on equity of -31.10% beat Molecular Partners' return on equity.
Summary
Omega Therapeutics beats Molecular Partners on 13 of the 18 factors compared between the two stocks.
Get Omega Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMGA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OMGA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Omega Therapeutics Competitors List
Related Companies and Tools
